Monday, June 6
12:00 - 12:25pm ET
sponsored by Astra Zeneca

Fireside Chat with Arsalan Arif

Chatrick Paul
Chatrick Paul
Senior Vice President, Head of US Oncology Business Unit
AstraZeneca
Arsalan Arif
Arsalan Arif
Publisher & Founder
Endpoints News
Monday, June 6
12:30 - 1:30pm ET
sponsored by Catalent

ASCO highlights

What’s hot at ASCO? And what just went cold? Our panel of experts will examine the top stories to come out of the year’s big cancer drug conference.

John Connolly
John Connolly
Chief Scientific Officer
Parker Institute for Cancer Immunotherapy
Dietmar Berger
Dietmar Berger
Chief Medical Officer, Global Head of Development
Sanofi
Alice T. Shaw
Alice T. Shaw
Global Head of Translational Clinical Oncology
Novartis Institutes for BioMedical Research (NIBR)
Tyler Jacks
Tyler Jacks
President
Break Through Cancer
John Carroll
John Carroll
Editor & Founder
Endpoints News
moderator
Tuesday, June 7
11:00am - 11:45am ET
sponsored by Novotech

Accelerating clinical development in China & the US

China and the US are the world’s largest oncology research destinations, and the clinical research bridge between them supports accelerated clinical development from early to late phase trials while ensuring the inclusion of MRCT data packages in future regulatory applications. With experienced clinical teams in both regions, Novotech will share real-world success strategies for biotechs undertaking global clinical development programs. Learn the latest on the clinical trial landscape and infrastructure in China and join Novotech’s DCT partner, Obvio Health, as they share DCT strategies for patient-centric, oncology study design and execution.

Peter Luo
Peter Luo
Co-Founder, Chief Executive Officer and Chairman
Adagene
Andy Liu
Andy Liu
General Manager
PPC China
Nancy Snowden
Nancy Snowden
Head of US Operations
Novotech
Vivian Gu
Vivian Gu
Head of CDR
China CMO
Jin Li
Jin Li
Professor of the Department of Oncology
Shanghai East Hospital
Susan Dallabrida
Susan Dallabrida
CEO and Chairman
SPRIM, ObvioHealth
Arsalan Arif
Arsalan Arif
Publisher & Founder
Endpoints News
moderator
Tuesday, June 7
1:00 - 1:45pm ET
sponsored by Anheart

Next-generation ROS1 inhibitors for lung cancer – what’s next?

ROS1 is quickly emerging as a cancer target for lung cancer. ROS1 fusion mutations occur in 1-2% of non-small cell lung cancer (NSCLC) patients. In 2020, an estimated 1.8 million new cases of NSCLC were diagnosed globally. Next-generation ROS1 inhibitors such as taletrectinib are in development, which may have long durability of response, overcome drug resistance and cross the blood-brain barrier. AnHeart along with a panel of experts will examine some of the leading ROS1 programs and take a look at the latest precision oncology therapeutics being evaluated in the clinic for lung cancer.

David Ross Camidge
David Ross Camidge
Professor
University of Colorado
Caicun Zhou
Caicun Zhou
Professor
Shanghai Pulmonary Hospital
Misako Nagasaka
Misako Nagasaka
Associate Professor
University of California Irvine
Wei Li
Wei Li
Oncologist
Shanghai Pulmonary Hospital
Lihua Zheng
Lihua Zheng
Co-Founder & Chief Business Officer
AnHeart Therapeutics
Kimberly Ha
Kimberly Ha
CEO and Founder
KKH Advisors
moderator
Register for virtual panels

No cost to register, subject to confirmation

By registering for this event, you accept that you may receive direct communication from the sponsor(s).

If you are experiencing problems with your registration, please contact our support team.